IL-5 is a key driver of Type 2 inflammation in patients with severe asthma, promoting downstream effects like mucus plugging and epithelial barrier dysfunction. Given these impacts, targeted therapy with biologics can play a role in severe asthma management. Join Drs. Diego Maselli, Anju Peters, and Monica Kraft as they explore the impacts of IL-5 and share perspectives on patient selection and shared decision-making for targeted therapies. Dr. Maselli is a Professor of Medicine at the Long School of Medicine at UT Health in San Antonio. Dr. Peters is a Professor of Medicine and Associate Chief of Clinical Research and Practice Innovation at Northwestern Medicine in Chicago. Dr. Kraft is a System Chair of the Samuel Bronfman Department of Medicine and a Professor of Medicine at the Icahn School of Medicine at Mount Sinai Health Systems in New York.

This episode of Deep Breaths: Updates from CHEST was supported by a non-promotional, non-CME educational program brought to you by CHEST in collaboration with and sponsored by GSK.